TFA
MDGL icon

Transamerica Financial Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Transamerica Financial Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.76K Buy
7
+2
+40% +$1.02K ﹤0.01% 1191
2026
Q1 		$2.62K Buy
+5
New +$2.39K ﹤0.01% 1154
2025
Q4 		– Sell
-2
Closed -$917 – 1881
2025
Q3 		$917 Buy
+2
New +$746 ﹤0.01% 1185

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Transamerica Financial Advisors's MDGL Position: Q2 2026 in Review

Transamerica Financial Advisors increased its Madrigal Pharmaceuticals (MDGL) stake by 40% in Q2 2026, buying an estimated $1.02K and bringing the position to 7 shares worth $3.76K. The position accounts for ﹤0.01% of the portfolio, ranked #1191.

Transamerica Financial Advisors first reported a position in MDGL in Q3 2025 and has held it in 3 quarters since. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Transamerica Financial Advisors held 7 shares of Madrigal Pharmaceuticals worth $3.76K as of Q2 2026.
  • Transamerica Financial Advisors bought 2 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $1.02K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #1191 holding.
  • Transamerica Financial Advisors first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.